Shares of Kane Biotech Inc. (CVE:KNE – Get Free Report) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as C$0.03 and last traded at C$0.04, with a volume of 71191 shares trading hands. The stock had previously closed at C$0.03.
Kane Biotech Price Performance
The company’s 50 day moving average price is C$0.03 and its 200-day moving average price is C$0.04. The stock has a market cap of C$6.15 million, a P/E ratio of -1.50 and a beta of 0.97. The company has a quick ratio of 0.39, a current ratio of 0.45 and a debt-to-equity ratio of -135.17.
Kane Biotech Company Profile
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Further Reading
- Five stocks we like better than Kane Biotech
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
